Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival
Just over two years after spending more than $2 billion to acquire the drug, UCB announced that zilucoplan proved effective at treating the rare autoimmune …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
